Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Taofeek K Owonikoko

Showing results (1-10 of 189) with videos related to

Pageof 19
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|April 2, 2008
Small cell lung cancer in elderly patients: a reviewTaofeek K Owonikoko, Suresh Ramalingam
Current Treatment Options in Oncology|November 11, 2008
The role of targeted agents in the treatment of elderly patients with non-small cell lung cancer (NSCLC)Taofeek K Owonikoko, Suresh Ramalingam
Journal of Thoracic Disease|March 30, 2018
Immune checkpoint inhibitors in small cell lung cancerSuchita Pakkala, Taofeek K Owonikoko
Seminars in Oncology|February 26, 2014
Small cell lung cancer: therapies and targetsRathi N Pillai, Taofeek K Owonikoko
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulationTaofeek K Owonikoko, Fadlo R Khuri
Molecular Aspects of Medicine|July 19, 2015
Biomarkers and targeted systemic therapies in advanced non-small cell lung cancerMukesh Kumar, Vinicius Ernani, Taofeek K Owonikoko
Frontiers in Oncology|August 1, 2020
Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer TherapyBassel Nazha, Cengiz Inal, Taofeek K Owonikoko
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Enrollment of Racial Minorities in Clinical Trials: Old Problem Assumes New Urgency in the Age of ImmunotherapyBassel Nazha, Manoj Mishra, Rebecca Pentz, et al.
Clinical Lung Cancer|July 28, 2009
The role of cetuximab in the management of non-small-cell lung cancerTaofeek K Owonikoko, Shi-Yong Sun, Suresh S Ramalingam
Future Oncology (London, England)|November 26, 2020
Benefits and limitations of real-world evidence: lessons from <i>EGFR</i> mutation-positive non-small-cell lung cancerBassel Nazha, James C-H Yang, Taofeek K Owonikoko
Pageof 19

Showing results (1-10 of 189) with videos related to

Sort By:
Pageof 19
Journal of the National Comprehensive Cancer Network : JNCCN|April 2, 2008
Small cell lung cancer in elderly patients: a reviewTaofeek K Owonikoko, Suresh Ramalingam
Current Treatment Options in Oncology|November 11, 2008
The role of targeted agents in the treatment of elderly patients with non-small cell lung cancer (NSCLC)Taofeek K Owonikoko, Suresh Ramalingam
Journal of Thoracic Disease|March 30, 2018
Immune checkpoint inhibitors in small cell lung cancerSuchita Pakkala, Taofeek K Owonikoko
Seminars in Oncology|February 26, 2014
Small cell lung cancer: therapies and targetsRathi N Pillai, Taofeek K Owonikoko
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulationTaofeek K Owonikoko, Fadlo R Khuri
Molecular Aspects of Medicine|July 19, 2015
Biomarkers and targeted systemic therapies in advanced non-small cell lung cancerMukesh Kumar, Vinicius Ernani, Taofeek K Owonikoko
Frontiers in Oncology|August 1, 2020
Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer TherapyBassel Nazha, Cengiz Inal, Taofeek K Owonikoko
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
Enrollment of Racial Minorities in Clinical Trials: Old Problem Assumes New Urgency in the Age of ImmunotherapyBassel Nazha, Manoj Mishra, Rebecca Pentz, et al.
Clinical Lung Cancer|July 28, 2009
The role of cetuximab in the management of non-small-cell lung cancerTaofeek K Owonikoko, Shi-Yong Sun, Suresh S Ramalingam
Future Oncology (London, England)|November 26, 2020
Benefits and limitations of real-world evidence: lessons from <i>EGFR</i> mutation-positive non-small-cell lung cancerBassel Nazha, James C-H Yang, Taofeek K Owonikoko
Pageof 19